CA3047508A1 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
CA3047508A1
CA3047508A1 CA3047508A CA3047508A CA3047508A1 CA 3047508 A1 CA3047508 A1 CA 3047508A1 CA 3047508 A CA3047508 A CA 3047508A CA 3047508 A CA3047508 A CA 3047508A CA 3047508 A1 CA3047508 A1 CA 3047508A1
Authority
CA
Canada
Prior art keywords
herpes simplex
simplex virus
oncolytic herpes
tumor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3047508A
Other languages
English (en)
French (fr)
Inventor
Joe Conner
Timothy CRIPE
Original Assignee
Virttu Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1622214.3A external-priority patent/GB201622214D0/en
Priority claimed from GBGB1702565.1A external-priority patent/GB201702565D0/en
Application filed by Virttu Biologics Ltd filed Critical Virttu Biologics Ltd
Publication of CA3047508A1 publication Critical patent/CA3047508A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3047508A 2016-12-23 2017-12-22 Treatment of cancer Abandoned CA3047508A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1622214.3 2016-12-23
GBGB1622214.3A GB201622214D0 (en) 2016-12-23 2016-12-23 treatment of cancer
GB1702565.1 2017-02-17
GBGB1702565.1A GB201702565D0 (en) 2017-02-17 2017-02-17 Treatment of cancer
PCT/EP2017/084421 WO2018115458A1 (en) 2016-12-23 2017-12-22 Treatment of cancer

Publications (1)

Publication Number Publication Date
CA3047508A1 true CA3047508A1 (en) 2018-06-28

Family

ID=61189397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047508A Abandoned CA3047508A1 (en) 2016-12-23 2017-12-22 Treatment of cancer

Country Status (6)

Country Link
US (1) US20200000861A1 (enExample)
EP (1) EP3558377A1 (enExample)
JP (1) JP2020501589A (enExample)
CN (1) CN110869052A (enExample)
CA (1) CA3047508A1 (enExample)
WO (1) WO2018115458A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170133A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
US20230023987A1 (en) * 2019-12-20 2023-01-26 Board Of Regents, The University Of Texas System Methods for treating cancer comprising low dose radiation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP3153526B1 (en) * 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2013169739A1 (en) * 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
US9862932B2 (en) * 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2879707A4 (en) * 2012-08-01 2016-05-11 Tetralogic Pharm Corp Combination therapy
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
GB201408297D0 (en) * 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood

Also Published As

Publication number Publication date
EP3558377A1 (en) 2019-10-30
WO2018115458A1 (en) 2018-06-28
JP2020501589A (ja) 2020-01-23
US20200000861A1 (en) 2020-01-02
CN110869052A (zh) 2020-03-06

Similar Documents

Publication Publication Date Title
US10813958B2 (en) Use of oncolytic herpes simplex virus, alone or in combination with immune check-point inhibitor, in the treatment of cancer
Yun et al. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
Mahmoud et al. Advances in immunotherapy for glioblastoma multiforme
Yan et al. Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments
US20200171151A1 (en) Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
Bommareddy et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma
Streby et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients
Leoni et al. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
AU2020222239B2 (en) Car T-cells for the treatment of CD1a-positive cancer
US20200000861A1 (en) Treatment of cancer
Qi et al. Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
Ghonime et al. Chimeric HCMV/HSV-1 and Δγ134. 5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory
KR102950505B1 (ko) M2 결함성 폭스바이러스
Huang et al. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses
Alvarez-Breckenridge et al. Pharmacologic and chemical adjuvants in tumor virotherapy
Tsun et al. Oncolytic immunotherapy for treatment of cancer
Goins et al. Oncolytic HSV vectors and anti-tumor immunity
US20250032611A1 (en) Gene editing and engineering stem cells for drug delivery
Guinn et al. 8th international conference on oncolytic virus therapeutics
Frendéus et al. Vector-based Cancer Immunotherapy
HK40116152A (en) Car t-cells for the treatment of cd1a-positive cancer
Denton Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical models of Ewing sarcoma
Suryadevara CAR T-cell Immunotherapy for Brain Tumors
Smith Exploiting the Glioblastoma Tumor Microenvironment for Enhanced Oncolytic Herpes Simplex Virus Therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230622